ArticleAmerican journal of cancer research2025

TRAIL receptor agonist TLY012 in combination with PD-1 inhibition promotes tumor regression in an immune-competent mouse model of pancreatic ductal adenocarcinoma.

Anna D Louie et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.